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Association between FDA and EMA expedited approval  
programs and therapeutic value of new medicines: retrospective 
cohort study
Thomas J Hwang,1,2 Joseph S Ross,3,4,5 Kerstin N Vokinger,2,6 Aaron S Kesselheim1
ABSTRACT
Objective
To characterize the therapeutic value of new drugs 
approved by the US Food and Drug Administration 
(FDA) and European Medicines Agency (EMA) and the 
association between these ratings and regulatory 




New drugs approved by the FDA and EMA between 
2007 and 2017, with follow-up through 1 April 2020.
Data sOurces
Therapeutic value was measured using ratings of new 
drugs by five independent organizations (Prescrire 
and health authorities of Canada, France, Germany, 
and Italy).
Main OutcOMe Measures
Proportion of new drugs rated as having high 
therapeutic value; association between high 
therapeutic value rating and expedited status.
results
From 2007 through 2017, the FDA and EMA approved 
320 and 268 new drugs, respectively, of which 181 
(57%) and 39 (15%) qualified for least one expedited 
program. Among 267 new drugs with a therapeutic 
value rating, 84 (31%) were rated as having high 
therapeutic value by at least one organization. 
Compared with non-expedited drugs, a greater 
proportion of expedited drugs were rated as having 
high therapeutic value among both FDA approvals 
(45% (69/153) v 13% (15/114); P<0.001) and EMA 
approvals (67% (18/27) v 27% (65/240); P<0.001). 
The sensitivity and specificity of expedited program 
for a drug being independently rated as having high 
therapeutic value were 82% (95% confidence interval 
72% to 90%) and 54% (47% to 62%), respectively, for 
the FDA, compared with 25.3% (16.4% to 36.0%) and 
90.2% (85.0% to 94.1%) for the EMA.
cOnclusiOns
Less than a third of new drugs approved by the 
FDA and EMA over the past decade were rated as 
having high therapeutic value by at least one of five 
independent organizations. Although expedited 
drugs were more likely than non-expedited drugs to 
be highly rated, most expedited drugs approved by 
the FDA but not the EMA were rated as having low 
therapeutic value.
Introduction
Most novel medicines that are introduced in clinical 
practice globally are first approved by the US Food and 
Drug Administration (FDA) and European Medicines 
Agency (EMA).1 2 Over the past two decades, both 
regulatory agencies have established programs to 
expedite drug development and regulatory review 
for serious conditions. The FDA has four main 
expedited programs: fast track (introduced in 1987), 
accelerated approval (1992), priority review (1992), 
and breakthrough therapy (2012).3 The EMA has two 
such programs: accelerated assessment (2005) and 
conditional marketing authorisation (2006).4 5 The 
EMA launched a third program—the priority medicines 
scheme (PRIME)—in 2016.6 These expedited pro­
grams, which are intended to prioritize the most 
important medicines for faster access by patients, are 
increasingly the route by which most new medicines 
are approved.7 8 The FDA approved 60% of new drugs 
through at least one expedited program in 2019; by 
contrast, only 34% of drug approvals in 2000 were 
expedited.9
FDA and EMA guidance indicate that expedited 
programs generally should be reserved for drugs that 
are expected to provide an improvement over available 
therapies (table 1).3 4 However, neither the FDA nor the 
EMA specifically requires data on, or makes regulatory 
approval contingent on, comparative effectiveness; 
most new drugs are approved on the basis of placebo 
controlled trials or single arm studies.10 By contrast, 
after approval, health systems and payers generally 
decide to reimburse new drugs on the basis of their 
added benefit compared with existing therapies 
(table 2).11
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WHAT IS ALREADY KNOWN ON THIS TOPIC
New drugs are being approved by the US Food and Drug Administration (FDA) and 
European Medicines Agency (EMA) in greater quantity and with greater speed 
than ever before
This is due in part to programs designed to expedite drug development and 
approval
Some countries have independent organizations that help to determine which 
new drugs offer clinical benefits to patients over existing treatments
WHAT THIS STUDY ADDS
Less than a third of new drugs approved by the FDA and EMA were rated by any 
organization as having high therapeutic value
Expedited drug approvals were more likely to be rated as having high therapeutic 
value than were drugs not qualifying for any such expedited program
Policy makers and regulators should explore ways to better inform patients and 
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The therapeutic value of medicines benefiting from 
the FDA and EMA expedited programs is therefore 
uncertain. Using ratings of therapeutic value published 
by health authorities in four countries (Canada, 
France, Germany, and Italy) and an independent 
non­profit organization (Prescrire), we evaluated the 
association between expedited programs and ratings 
of therapeutic value for all new drugs approved by the 
FDA and EMA from 2007 through 2017.
Methods
study cohort
We used publicly available FDA (https://www.
accessdata.fda.gov/scripts/cder/daf/) and EMA 
(https://www.ema.europa.eu/en/search/search/ema_
group_types/ema_medicine) databases to identify all 
new drugs and biologic agents approved by the FDA 
and EMA, respectively, between 1 January 2007 and 
31 December 2017, excluding generic, biosimilar, 
diagnostic, contrast, and imaging agents. We chose 
this study timeframe to allow at least two calendar 
years of follow­up from the date of approval for an 
assessment of drugs’ therapeutic value. All data were 
updated through 1 April 2020.
expedited programs and regulatory status
Using methods that we described previously,12 we 
extracted key information from the FDA and EMA 
databases on each drug in our study cohort, including 
generic and brand names, therapeutic area (the 
World Health Organization’s Anatomic Therapeutic 
Classification system), date of approval, indication, 
expedited program(s), and orphan designation (rare 
disease, defined in the US (Orphan Drug Act) as 
affecting fewer than 200 000 people and in the EU 
(Orphan Regulation) as a prevalence of fewer than five 
in 10 000). Expedited programs were priority review, 
accelerated approval, fast track, and breakthrough 
therapy designation for the FDA and accelerated 
assessment and conditional marketing authorisation 
for the EMA. Drugs may qualify for more than one 
expedited program. As the PRIME program was 
established in 2016, no approvals had yet been made 
through this program by the end of 2017. We manually 
cross checked expedited program designations with 
publicly available review dossiers, reports, and annual 
summaries of new drug approvals.13 14
ratings of therapeutic value
We searched for ratings of therapeutic value published 
by drug regulatory, public health, or health technology 
assessment agencies in the US, Europe, and Canada. 
No rating agencies were identified in the US. In Europe, 
several health technology assessment agencies publish 
only a decision on coverage, without providing a 
rating of the level of added benefit, and were therefore 
excluded (for example, the National Institute for 
Health and Care Excellence).15 We identified four 
national organizations that publish therapeutic value 
ratings in Canada (Human Drug Advisory Panel),16 
France (Ministry of Health),17 Germany (Federal Joint 
Committee),18 and Italy (Italian Medicines Agency).19 
We also included a non­profit organization, Prescrire, 
which publishes a monthly medical journal that 
reviews new treatments for healthcare professionals.20 
This resulted in five organizations that assess new 
drugs according to the level of added benefit and public 
health relevance and subsequently publish ratings of 
therapeutic value (table 2). All included organizations 
did not consider cost or cost effectiveness in their 
ratings and were independent from the pharmaceutical 
industry.
study outcomes
We defined ratings of moderate or greater therapeutic 
value as “high” and the rest (that is, minor, possible, not 
quantified, and no/slight benefit) as “low,” consistent 
with cut­off values for favorable reimbursement and 
coverage decisions by the national authorities. We 
focused on the rating for the indication at the time 
of first FDA or EMA approval. When multiple ratings 
were provided by an organization for a single drug (for 
example, for different subgroups or disease stages), 
we used the most favorable rating received at the 
table 1 | characteristics of us Food and Drug administration (FDa) and european Medicines agency (eMa) expedited 
programs
expedited program Year Qualifying criteria Program benefits
FDa




1992 Meaningful advantage over available therapies  
and demonstrates effect on surrogate endpoint  
reasonably likely to predict clinical benefit
Approval based on surrogate  
endpoint or intermediate clinical endpoint
Priority review 1992 Significant improvement in safety or effectiveness Shorter FDA review time  
(6 months instead of standard 10 months)
Breakthrough  
therapy
2012 Substantial improvement on a clinically  
significant endpoint over available therapies
Intensive guidance and organizational  
commitment on efficient drug development; 





2005 Major interest for public health  
and therapeutic innovation
Shorter EMA review time  
(150 days instead of standard 210 days)
Conditional marketing 
authorisation
2006 Benefit to public health of immediate availability  
outweighs risk of less comprehensive data than usual
Less comprehensive evidence at time of initial 
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time of the drug’s approval for any subpopulation or 
clinical setting included in the approved indication. 
The primary outcome was the highest rating provided 
by any organization, which was chosen to provide the 
most generous estimate of the number of drugs rated 
highly. We also included a more restrictive definition—
drugs rated highly by more than one organization—as 
a secondary outcome.
statistical analysis
We used descriptive statistics to analyze the proportion 
of new drugs rated highly by any organization 
and logistic regression models with approval year 
and an indicator variable for expedited status to 
examine trends in new highly rated drugs. To identify 
factors associated with being rated highly, we used 
multivariable logistic regression models that included 
indicator variables for therapeutic area, a linear term 
for approval year, separate indicator variables for 
each expedited program, and an indicator variable 
for orphan drug designation. We also assessed 
the sensitivity, specificity, and area under receiver 
operating characteristic curves of any expedited 
program and each expedited program separately for 
a high rating. In a sensitivity analysis, we repeated 
our unadjusted and adjusted analyses examining the 
association between expedited program and high 
therapeutic value rating in the subgroup of drugs 
assessed by more than one organization. We used 
Stata version 12 for all analyses and considered 
two tailed P values under 0.05 to be statistically 
significant.
Patient and public involvement
No patients were involved in setting the research 
question or the outcome measures, nor were they 
involved in developing plans for design or implemen­
tation of the study. However, we plan to disseminate 
results directly to patients through interactive online 
tools.
Results
From 2007 through 2017, the FDA approved 320 
new medicines and the EMA approved 268 new 
medicines (table 3). As of 1 April 2020, 239 (75%) of 
the FDA’s new drug approvals were also approved by 
the EMA, and an additional 15 (5%) were approved 
through national approval procedures. Most new 
drugs approved by the FDA and EMA were indicated 
to treat oncologic (25% and 31%, respectively), 
alimentary and metabolic (13% and 13%), or blood 
and cardiovascular (12% and 11%) disorders. Among 
the 320 new drugs approved by the FDA, 181 (57%) 
qualified for at least one expedited program, and 
roughly half (163; 51%) qualified for priority review. 
By contrast, 39 (15%) of the 268 new drugs approved 
by the EMA qualified for either accelerated assessment 
or conditional marketing authorisation.
ratings of therapeutic value
Ratings of therapeutic value by one of the organizations 
included in the study were available for 267 drugs 
(83% of FDA approvals; all but one of EMA approvals). 
Overall, 31% (84/267) of FDA drug approvals and 31% 
(83/267) of EMA drug approvals were rated as having 
high therapeutic value by at least one organization. 
Drugs that were approved by the FDA but not the 
EMA were less likely than drugs approved by both 
regulators to be rated as having high therapeutic value 
(14% v 33%; odds ratio 3.02, 95% confidence interval 
1.01 to 9.02; P=0.04). The relative proportion of drug 
approvals rated as having high therapeutic value did 
not change over the study period for either the FDA 
(odds ratio for time trend 1.00, 0.92 to 1.08; P=0.92) 
(fig 1) or the EMA (1.00, 0.92 to 1.09; P=0.92).
association between FDa’s expedited programs and 
high ratings
Among FDA approved drugs with at least one available 
therapeutic value rating, 45% (69/153) of expedited 
drugs (qualified for at least one expedited program) 
table 2 | comparison of scope and therapeutic value ratings of regulatory agencies and health authorities included in study
agency or organization country relevant key aims and scope therapeutic value rating
Pre-approval
FDA USA Approval (if drug benefits outweigh known risks)  
permits market entry
None
EMA EU Authorization (considering efficacy and safety) permits  
market entry in all EU member states and EEA*
None
Post-approval
Human Drug Advisory Panel 
(HDAP)
Canada Reviews and evaluates scientific information on patented drugs; 
makes recommendations on level of therapeutic improvement to 
Canada’s Patented Medicine Prices Review Board
Ratings of breakthrough/substantial improvement, 
moderate improvement, or slight/no improvement
Transparency Committee,  
Ministry of Health (HAS)
France Assesses drugs’ clinical benefit and added value compared with 
available treatments and provides recommendations for  
inclusion on lists of reimbursable products
Ratings of major, considerable, moderate, or minor 
added benefit or no or not quantified benefit
Federal Joint Committee (G-BA) Germany Assesses additional benefit over appropriate comparator;  
resolution based on benefit assessment serves as basis for  
negotiation of reimbursement price
Ratings of major, considerable, minor,  
or no or not quantified benefit
Italian Medicines Agency (AIFA) Italy National drug regulatory agency assesses therapeutic  
innovativeness of new drug approvals
Ratings of important innovation, innovative,  
potential or conditional innovation, or not innovative
AIFA=Agenzia Italiana del Farmaco; EEA=European Economic Area (Iceland, Liechtenstein, and Norway); EMA=European Medicines Agency; FDA=US Food and Drug Administration; 
G-BA=Gemeinsamer Bundesausschuss; HAS=Haute Autorité de Santé.
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were rated as having high therapeutic value, compared 
with 13% (15/114) of non­expedited drugs (P<0.001). 
The number of qualifying expedited programs was 
also associated with the proportion of drugs rated as 
having high therapeutic value: 49% (29/59) of drugs 
qualifying for two and 65% (26/40) of drugs qualifying 
for three or more expedited programs were rated as 
having high therapeutic value, compared with 26% 
(14/54) qualifying for only one expedited program 
(P<0.001) (fig 2).
In multivariable logistic regression analysis adjus­
ting for therapeutic area, orphan designation, time 
trends, and each expedited program separately, drugs 
qualifying for priority review (odds ratio 3.93, 1.73 
to 8.91; P=0.001), fast track (3.09, 1.51 to 6.33; 
P=0.002), and breakthrough therapy designation 
(4.34, 1.57 to 12.0; P=0.005) were associated with 
greater odds of being rated as having high therapeutic 
value than drugs not qualifying for those programs 
(table 4). Accelerated approval was not associated with 
greater odds of being rated as having high therapeutic 
value (odds ratio 1.02, 0.40 to 2.61; P=0.96).
Overall, the sensitivity and specificity of qualifying 
for any FDA expedited program for a drug being 
independently rated as having high therapeutic value 
were 82% (95% confidence interval 72% to 90%) and 
54% (47% to 62%), respectively (table 5). Expedited 
program was not a strong predictor of high therapeutic 
value rating overall (area under receiver operating 
characteristic curve 0.68, 95% confidence interval 
0.63 to 0.74) and similarly for each expedited program 
separately: 0.70 (0.65 to 0.76) for priority review, 
0.67 (0.61 to 0.73) for fast track, 0.55 (0.50 to 0.59) 
for accelerated approval, and 0.70 (0.62 to 0.78) for 
breakthrough therapy designation.
association between eMa’s expedited programs 
and high ratings
Among EMA approved drugs with at least one available 
rating, a greater proportion of drugs qualifying than 
not qualifying for accelerated assessment were rated 
as having high therapeutic value (67% (18/27) v 
27% (65/240); P<0.001). This was not the case for 
conditional marketing authorisation (31% (4/13) v 
31% (79/254); P=0.98).
In multivariable logistic regression analysis adjus­
ting for therapeutic area, orphan designation, time 
trends, accelerated assessment, and conditional 
marketing authorisation, drugs qualifying for accele­
rated assessment (odds ratio 3.73, 1.49 to 9.31; 
P=0.005) and orphan designation (2.31, 1.09 to 4.86; 
P=0.03) were associated with greater odds of being 
rated as having high therapeutic value than drugs not 
qualifying for those programs (table 4). Conditional 
marketing authorisation was not associated with 
greater odds of being rated as having high therapeutic 
value (odds ratio 0.54, 0.17 to 1.68; P=0.29).
The sensitivity and specificity of qualifying for any 
EMA expedited program (accelerated assessment or 
conditional marketing authorisation) for a drug being 
independently rated as having high therapeutic value 
were 25% (16% to 36%) and 90% (85% to 94%), 
respectively. The sensitivity, specificity, and area under 
receiver operating characteristic curve of accelerated 
assessment for a high therapeutic value rating were 22% 
(13% to 32%), 95% (91% to 98%), and 0.58 (0.54% 
to 0.63); for conditional marketing authorization, they 
were 5% (1% to 12%), 95% (91% to 98%), and 0.50 
(0.47% to 0.53), respectively (table 5).
table 3 | characteristics of novel therapeutic approvals for us Food and Drug 
administration (FDa) and european Medicines agency (eMa) between 2007 and 2017. 
values are numbers (percentages)
characteristics FDa 2007-17 (n=320) eMa 2007-17 (n=268)
Therapeutic area:
 Alimentary and metabolism 43 (13) 34 (137)
 Blood and cardiovascular 39 (12) 30 (11)
 Anti-infective 39 (12) 35 (13)
 Cancer 80 (25) 83 (31)
 Neurologic and autoimmune 39 (12) 33 (12)
 Respiratory 34 (11) 21 (8)
 Sensory and others 46 (14) 32 (12)
Approval year:
 2007-11 110 (34) 100 (37)
 2012-17 210 (66) 168 (63)
Rating available 267 (83) 267* (100)
Orphan designation 123 (38) 50 (19)
FDA expedited program†:
 Priority review 163 (51) -
 Accelerated approval 42 (13) -
 Fast track 101 (32) -
 Breakthrough therapy‡ 46 (14) -
EMA expedited program§:
 Accelerated assessment - 27 (10)
 Conditional marketing authorisation - 13 (5)
No of FDA expedited programs†:
 None 139 (43) -
 1 63 (20) -
 2 72 (23) -
 ≥3 46 (14) -
No of EMA expedited programs†:
 None - 229 (85)
 ≥1 - 39 (15)
*Ferric maltol (Ferracru) did not have any available ratings.
†Drugs may qualify for more than one expedited program.
‡Created in 2012.
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Expedited
Non-expedited
Fig 1 | temporal trends in proportion of FDa expedited versus non-expedited drugs 
rated as having high therapeutic value, 2007-17. Figure shows proportion over time of 
expedited (qualified for ≥1 expedited program) and non-expedited program drugs rated 
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sensitivity analyses
Of 267 drugs with any available therapeutic value 
rating, 245 (92%) were assessed by more than one 
organization; of these, 50 (20%) were rated as having 
high therapeutic value by more than one organization. 
Nearly all of them (48/50; 96%) qualified for an 
expedited program. We obtained substantively similar 
results when we repeated the unadjusted and adjusted 
analyses with this secondary outcome of drugs rated 
highly by more than one organization and with the 
primary outcome in the subgroup of drugs with ratings 
available from more than one organization.
Discussion
We found that less than a third of all new drugs 
approved by the FDA and EMA were rated by any of five 
independent organizations as having high therapeutic 
value—that is, providing moderate or better improve­
ment in clinical outcomes for patients. Most of the 
increase in the number of new drug approvals over 
the past decade was driven by drugs rated as having 
low therapeutic value, which calls into question the 
common practice of using simple counts of new drug 
approvals as a measure of innovation.21­23 Rather, a 
more nuanced view of innovation is needed that takes 
into account the clinical benefits and relevance to 
patients of new medicines.
Expedited drugs were more likely than non­expedited 
drugs to be rated as having high therapeutic value. 
Stratified by expedited program, drugs qualifying for 
priority review, fast track, and breakthrough therapy 
designation by the FDA or accelerated assessment by 
the EMA were more likely than drugs not qualifying for 
those programs to be rated highly. Few non­expedited 
drugs were highly rated. However, in absolute terms, 
most drugs in the FDA’s expedited programs were 
rated as having low therapeutic value—even for 
breakthrough designated therapies and those that 
qualified for priority review, which is intended for 
drugs that provide “significant improvement.” By 
contrast, few drugs qualified for the EMA’s accelerated 
assessment, but most of them were rated highly.
implications of findings
The study findings, which are consistent with a 
previous study of FDA designated breakthrough cancer 
drugs and an analysis stratifying new drug approvals 
by novelty of mechanism of action,24­26 suggest a 
widening gap between regulatory approval and the 
clinical and public health priorities of health systems, 
payers, and patients after approval. Contributing to 
this may be the varying quality of clinical trial evidence 
available at the time of approval and resulting 
uncertainty around the extent of clinical benefit.27­29 
As more evidence accumulates after approval, the 
assessment of therapeutic value may also evolve.
These data emphasize the importance of robust 
postmarketing evaluation for expedited drugs. Such an 
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Fig 2 | Proportion of new drugs approved by FDa and eMa rated as having high therapeutic value. Figure shows proportions of new medicines 
approved by FDa and eMa rated as having high therapeutic value stratified by type of expedited program (left panels) and number of expedited 
programs (right panels). error bars represent 95% cis. aa=accelerated approval; bt=breakthrough therapy designation; cMa=conditional marketing 
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evaluation would confirm early evidence of efficacy and 
help to elucidate findings from several previous studies 
suggesting that accelerated approval, priority review, 
and fast track drugs were associated with increased 
safety related reports or labeling changes.30­33 Greater 
assurance of timely completion of postmarketing 
study requirements for expedited drugs could be 
achieved by requiring that certain mandated studies 
begin enrolling patients before the FDA or EMA grants 
approval. In addition, regulators should account for 
the high expectations that physicians and patients 
have of the therapeutic value of drugs qualifying for 
expedited programs.34 In one national survey of board 
certified internists and specialists in the US, 77% of 
respondents believed that high quality evidence shows 
that a drug is more effective than existing treatments if 
it was designated as a “breakthrough” by the FDA, and 
94% preferred a hypothetical cancer drug described 
as a “breakthrough” over an equally effective alterna­
tive without that descriptor.35 Regulatory agencies 
should explore whether additional explanations or 
disclaimers are necessary, such as in product labeling, 
table 4 | Multivariable logistic regression analysis of novel therapeutic agents approved by us Food and Drug 
administration (FDa) and european Medicines agency (eMa) between 2007 and 2017 rated as having high therapeutic 
value. values are odds ratios (95% cis)
characteristic
FDa eMa
Odds of high rating* P value Odds of high rating* P value
therapeutic area:
 Alimentary and metabolism 1 (reference) 1 (reference)
 Blood and cardiovascular 0.25 (0.07 to 0.93) 0.04 0.24 (0.06 to 1.04) 0.06
 Anti-infective 0.50 (0.16 to 1.54) 0.23 1.89 (0.70 to 5.10) 0.21
 Cancer 0.41 (0.15 to 1.14) 0.09 1.36 (0.58 to 3.18) 0.47
 Neurologic and autoimmune 1.10 (0.31 to 3.94) 0.88 1.07 (0.37 to 3.07) 0.91
 Respiratory 0.18 (0.04 to 0.88) 0.04 0.11 (0.01 to 0.96) 0.05
 Sensory and others 0.66 (0.18 to 2.46) 0.54 0.53 (0.16 to 1.74) 0.30
Orphan designation:
 Yes 0.85 (0.39 to 1.84) 0.68 2.31 (1.09 to 4.86) 0.03
 No 1 (reference) - 1 (reference) -
FDa expedited programs
Priority review:
 Yes 3.93 (1.73 to 8.91) 0.001 - -
 No 1 (reference) - - -
Accelerated approval:
 Yes 1.02 (0.40 to 2.61) 0.96 - -
 No 1 (reference) - - -
Fast track:
 Yes 3.09 (1.51 to 6.33) 0.002 - -
 No 1 (reference) - - -
Breakthrough therapy:
 Yes 4.34 (1.57 to 11.99) 0.005 - -
 No 1 (reference) - - -
eMa expedited programs
Accelerated assessment:
 Yes - - 3.73 (1.49 to 9.31) 0.005
 No - - 1 (reference) -
Conditional marketing authorization:
 Yes - - 0.54 (0.17 to 1.68) 0.29
 No - - 1 (reference) -
*Estimates from multivariable logistic regression of any high therapeutic value rating.
table 5 | sensitivity, specificity, and area under receiver operating characteristic curve (auc) of us Food and 
Drug administration (FDa) and european Medicines agency (eMa) expedited programs for drug approvals being 
independently rated as high therapeutic value
characteristic sensitivity: % (95% ci) specificity: % (95% ci) auc (95% ci)
FDa expedited programs
Any FDA expedited program 82.1 (72.3 to 89.6) 54.1 (46.6 to 61.5) 0.68 (0.63 to 0.74)
Priority review 79.8 (69.6 to 87.7) 60.7 (53.2 to 67.8) 0.70 (0.65 to 0.76)
Accelerated approval 19.0 (11.3 to 29.1) 90.2 (84.9 to 94.2) 0.55 (0.50 to 0.59)
Fast track 54.8 (43.5 to 65.7) 79.2 (72.6 to 84.9) 0.67 (0.61 to 0.73)
Breakthrough therapy* 56.5 (41.4 to 71.1) 83.3 (74.4 to 90.2) 0.70 (0.62 to 0.78)
eMa expedited programs
Any EMA expedited program 25.3 (16.4 to 36.0) 90.2 (85.0 to 94.1) 0.58 (0.53 to 0.63)
Accelerated assessment 21.7 (13.4 to 32.1) 95.1 (90.9 to 97.7) 0.58 (0.54 to 0.63)
Conditional marketing authorisation 4.8 (1.3 to 11.9) 95.1 (90.9 to 97.7) 0.50 (0.47 to 0.53)
Drugs may qualify for more than one expedited program.
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press releases, or approval documents, to provide more 
realistic expectations of benefit for expedited drug 
approvals by patients and clinicians, as they already 
do in labels for drugs with accelerated approval.
Our study findings have implications for the 
ongoing controversy around drug prices. In the US, 
the largest public payers are required by law to cover 
most (Medicaid) or a substantial number (Medicare) of 
drugs approved by the FDA, regardless of the quality 
of the evidence supporting their approval or their 
therapeutic value.36 37 Previous studies of cancer drugs 
have found no association between clinical benefit 
and drug prices and reimbursement.38­41 Recent 
proposals to allow public payers to prioritize coverage 
of high value products, or to vary reimbursement rates 
based on effectiveness,42 could help to stretch limited 
budgets and attenuate incentives for the development 
of, and investment in, medical technologies providing 
marginal or unknown benefits.43­45 The US could 
learn from the experience of countries in Europe that 
have integrated assessment of clinical benefit into 
their reimbursement decisions. Canada, France, and 
Germany generally permit higher prices for highly 
rated drugs, while subjecting drugs with low ratings 
to reference pricing (that is, priced no higher than 
comparators) or possible formulary exclusion.
limitations of study
The study had several limitations. Firstly, we focused 
on initial approval, as this represents the critical 
clinical and coverage entry point of new therapies; the 
therapeutic value of supplemental and unapproved 
uses may differ. Secondly, we did not assess expedited 
program designations before approval, which were 
not publicly available. Thirdly, 17% of FDA approved 
drugs did not have an available rating, mainly because 
they were not approved in Europe or Canada and 
therefore not subject to assessment of benefit. Given 
our finding that drugs that were approved by the FDA 
but not the EMA were less likely than drugs approved 
by both regulators to be rated highly, our estimates 
may overestimate the proportion of drug approvals 
considered high therapeutic value. Finally, although 
the criteria and frameworks for benefit assessments 
were broadly similar across rating organizations, 
the methods and scoring system for individual 
organizations can also be influenced by country 
specific factors and assumptions.46 To be conservative, 
we focused on the primary outcome of the highest 
rating provided by any rating organization. We also did 
sensitivity analyses limited to drugs rated by multiple 
organizations as having high therapeutic value, which 
confirmed the primary results.
conclusions
The FDA and EMA are increasingly using expedited 
programs to facilitate the development of new drugs, 
and drugs approved through expedited programs were 
more likely than non­expedited drugs to be rated as 
having high therapeutic value. However, the absolute 
number of highly rated drugs approved by the FDA and 
EMA over the past decade was low, and the proportion 
of drugs rated as having high therapeutic value did 
not change over time. Policy makers and regulators 
could explore implementing therapeutic value ratings 
more broadly for new drug approvals, aligning 
the evidentiary needs of regulatory approval and 
reimbursement decisions, and informing patients and 
physicians about the benefits and risks of new drugs, 
especially those approved via expedited programs.
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